We're working on adding all of our packages. Stay tuned or get in touch if you don't see what you're looking for!

Target Identification Data Package

This package has 10 modules. The Drug Interactions Module has 3 tables. Preview the first five rows of each table or Explore the schema

Drug Interactions Module

3 Tables

The Drug-Drug Interactions data module describes drugs that, when administered concomitantly with the drug of interest, will affect its activity or result in adverse effects. These interactions may be synergistic or antagonistic depending on the physiological effects and mechanism of action of each drug. Each interaction description includes a summary description and detailed description of the mechanism of the interaction, as well as management information, a severity rating, and type of evidence.

Limited Drug-Drug Interactions

Each entry ties pairs of drugs with a simplified description of the interaction between them. This is a simplified/unstructured form of the data available in structured_drug_interactions.

subject_drug_id
affected_drug_id
description
1
6
The risk or severity of bleeding can be increased when Lepirudin is combined with Bivalirudin.
1
8
The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a.
1
9
The risk or severity of bleeding can be increased when Alteplase is combined with Lepirudin.
1
11
The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1.
1
13
Urokinase may increase the anticoagulant activities of Lepirudin.
Want all 2,828,756 rows? Let's connect you to sales.

Food Interactions

Each row describes an interaction between a food and a drug, linked by the drug_id column.

id
drug_id
description
267
1076
Avoid grapefruit products. Grapefruit products may increase the risk for atorvastatin related adverse effects such as myopathy and rhabdomyolysis.
281
490
Avoid grapefruit products. Grapefruit increases the plasma concentrations of the drug.
342
254
Avoid multivalent ions. The absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium.
352
492
Avoid hypertensive herbs (e.g. bayberry, blue cohosh, cayenne, ephedra, and licorice).
356
695
Increase consumption of potassium-rich foods. This medication may cause potassium depletion. Foods containing potassium include bananas and orange juice.
Want all 2,481 rows? Let's connect you to sales.

Complete Drug-Drug Interactions

Each entry ties pairs of drugs with a complete, structured description of the interaction between them. Each row represents a single structured drug-drug interaction.

id
subject_drug_id
subject_drug_drugbank_id
subject_drug_name
subject_dosage
affected_drug_id
affected_drug_drugbank_id
affected_drug_name
affected_dosage
summary
extended_description
severity
evidence_level
management
action
subject_category_id
affected_category_id
conditions
79938106
5
DB00005
Etanercept
8892
DB08879
Belimumab
The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab.
According to the FDA label, no studies have been done on the interactions between belimumab and other biologics, and thus usage is not recommended. Etanercept is a TNF blocker that increases the risk for infections [A35092] and taken together with belimumab could increase their immunosuprresive properties and risks for serious infections [A35091, L3602].
2
1
increase_adverse_effects
79938142
5
DB00005
Etanercept
531
DB00531
Cyclophosphamide
The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.
The FDA label states that the concurrent use of cyclophosphamide and etanercept is not recommended. Patients with severe Wegener's granulomatosis who received cyclophosphamide and etanercept had an increased risk of solid cancers compared with patients who received cyclophosphamide alone and was not associated with improved clinical outcomes [A35102]. As well, concurrent use of myelosuppressive anti-rheumatic agents has been associated with pancytopenia, including aplastic anemia, in some patients treated with etanercept [L3602].
2
1
increase_adverse_effects
79938145
6644
DB06643
Denosumab
5
DB00005
Etanercept
The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.
The coadministration of denosumab with immunosuppressive agents poses a high risk of serious infection than with denosumab alone.[A33465, L3013,F151]
1
1
Before administering this combination, thoroughly assess the risk versus benefit of concomitant administration. Monitor for infections during concurrent use. If serious infections develop, the clinical need for denosumab should be reassessed.[F151]
increase_adverse_effects
47
79938148
6644
DB06643
Denosumab
8
DB00008
Peginterferon alfa-2a
The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon alfa-2a.
The coadministration of denosumab with immunosuppressive agents poses a high risk of serious infection than with denosumab alone.[A33465, L3013,F151]
1
1
Before administering this combination, thoroughly assess the risk versus benefit of concomitant administration. Monitor for infections during concurrent use. If serious infections develop, the clinical need for denosumab should be reassessed.[F151]
increase_adverse_effects
47
79938151
6644
DB06643
Denosumab
11
DB00011
Interferon alfa-n1
The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-n1.
The coadministration of denosumab with immunosuppressive agents poses a high risk of serious infection than with denosumab alone.[A33465, L3013,F151]
1
1
Before administering this combination, thoroughly assess the risk versus benefit of concomitant administration. Monitor for infections during concurrent use. If serious infections develop, the clinical need for denosumab should be reassessed.[F151]
increase_adverse_effects
47
Want all 1,414,378 rows? Let's connect you to sales.

Showing 3 of 3 tables